Genotyping Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Reagents & Kits, Software and Services), By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others), By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others), By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 16.72 Billion
CAGR (2026-2031)	8.88%
Fastest Growing Segment	Sequencing
Largest Market	North America
Market Size (2031)	USD 27.86 Billion

Market Overview

The Global Genotyping Market will grow from USD 16.72 Billion in 2025 to USD 27.86 Billion by 2031 at a 8.88% CAGR. Genotyping is the analytical process of determining differences in the genetic constitution of an individual by comparing their DNA sequence against a reference standard. The global market is primarily propelled by the rising prevalence of chronic genetic diseases and the integral role of genomic analysis in pharmacogenomics and targeted therapy development. This increasing reliance on genetic insights for disease management is substantiated by recent data; according to the American Cancer Society, in 2025, it was projected that approximately 2,041,910 new cancer cases would be diagnosed in the United States alone, underscoring the critical global demand for precision oncology and genetic profiling technologies.

Despite these strong growth catalysts, the market encounters a significant challenge regarding data privacy and security. The generation of vast amounts of sensitive genetic information requires adherence to rigorous regulatory standards, which often vary by region and jurisdiction. These compliance obligations create substantial operational complexities and liability risks for diagnostic providers and research institutions, ultimately acting as a barrier to the seamless exchange of genomic data necessary for large-scale research and the broader clinical implementation of genotyping services.

Key Market Drivers

Substantial cost reductions in DNA sequencing and genomic analysis constitute a primary engine for market expansion, democratizing access to genetic data across clinical and research sectors. As high-throughput technologies mature, the unit cost per genome has plummeted, allowing laboratories to process vast sample volumes that were previously financially prohibitive. This economic shift directly fuels the scalability of population-health studies and commercial diagnostics, driving a surge in consumable usage and service contracts. Demonstrating this operational scaling, according to Illumina, May 2025, in the 'Q1 2025 Earnings Call', total sequencing gigabase output on connected high- and mid-throughput instruments increased by more than 30 percent year-over-year, reflecting the intense demand for affordable genomic data generation. Furthermore, the capacity for large-scale analysis is evident in public initiatives; according to UK Biobank, in 2025, the organization released comprehensive metabolomics data for 500,000 participants, a milestone made possible by these affordable, industrial-scale genotyping capabilities.

The expansion of precision medicine and pharmacogenomics applications serves as the second critical driver, fundamentally reshaping therapeutic development and patient care strategies. Pharmaceutical companies and clinicians are increasingly relying on genotypic data to identify biomarkers that predict drug efficacy and toxicity, thereby minimizing adverse events and optimizing treatment outcomes. This transition from one-size-fits-all healthcare to targeted regimens is heavily supported by regulatory trends favoring biomarker-driven development. According to the Personalized Medicine Coalition, May 2025, in the 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024' report, the FDA approved 18 new personalized medicines, which accounted for 38 percent of all newly approved therapeutic molecular entities, highlighting the central reliance on genetic profiling in modern drug discovery and approval processes.

Download Free Sample Report

Key Market Challenges

Data privacy and security represent a critical challenge that significantly hampers the growth of the Global Genotyping Market. As the industry relies on aggregating massive datasets of sensitive genetic profiles to fuel pharmacogenomics and precision medicine, it becomes a prime target for cyber threats. The necessity of adhering to rigorous and often fragmented regulatory standards across different jurisdictions creates substantial operational bottlenecks. These compliance obligations force organizations to divert resources toward defensive infrastructure rather than innovation, complicating the cross-border sharing of genomic data which is essential for validating biomarkers and advancing large-scale research.

The liability risks associated with maintaining these data pools cause stakeholders to restrict access, directly stalling clinical implementation. The magnitude of this vulnerability is illustrated by recent industry data. According to the American Hospital Association, in 2024, cyberattacks and data breaches within the healthcare sector impacted a record of 259 million individuals in the United States. Such widespread security failures erode patient trust and compel diagnostic providers to implement restrictive data silos, effectively blocking the seamless information exchange required for the market's continued expansion.

Key Market Trends

The Integration of Artificial Intelligence for Genotypic Data Interpretation is emerging as a pivotal trend, addressing the analytical bottlenecks created by the exponential growth of genomic datasets. As sequencing outputs scale, the market is shifting toward AI-driven platforms that automate complex variant classification and clinical reporting, moving beyond manual bioinformatics pipelines. This demand for computational efficiency is reflected in the rapid financial expansion of specialized providers; according to Tempus AI Inc., November 2024, in the 'Third Quarter 2024 Results', the company's data and services revenue, which encompasses its AI-enabled data platform, accelerated by 64.4 percent year-over-year to reach $64.5 million. This surge underscores the industry's increasing reliance on intelligent algorithms to convert raw genotypic data into actionable precision medicine insights.

Simultaneously, the Increasing Application in Agricultural Biotechnology and Animal Breeding is broadening the market's scope beyond human healthcare, utilizing genotyping to enhance food security and livestock productivity. Agribusinesses are extensively adopting genomic selection tools to identify desirable traits such as disease resistance and feed efficiency, thereby optimizing breeding programs and reducing operational risks. Despite broader economic adjustments in the sector, the reliance on these technologies remains robust; according to Neogen Corporation, July 2024, in the 'Annual Report 2024', the company's Genomics Services revenue increased by 8 percent in fiscal 2024 compared to the prior fiscal year. This resilience highlights the critical function of genotyping in modernizing agricultural supply chains and ensuring sustainable production standards.

Segmental Insights

The Sequencing segment is currently the fastest-growing portion of the Global Genotyping Market, largely due to the declining costs and improved accessibility of Next-Generation Sequencing technologies. This method offers a higher capacity for analyzing complex genetic data compared to older techniques, making it essential for modern research. The growth is also fueled by the increasing focus on personalized medicine, where medical professionals use genetic information to tailor treatments for patients. This trend is supported by regulatory bodies like the U.S. Food and Drug Administration (FDA), which have established clear standards for using sequencing data in clinical trials, thereby encouraging widespread adoption.

Regional Insights

North America dominates the Global Genotyping Market due to the extensive adoption of precision medicine and a robust healthcare infrastructure. The region benefits from the strong presence of major biotechnology and pharmaceutical companies that drive innovation in drug discovery and genetic analysis. Government support plays a critical role, with the National Institutes of Health providing substantial funding for genomic research programs. Furthermore, the U.S. Food and Drug Administration fosters market growth by establishing clear regulatory frameworks that encourage the integration of pharmacogenomics into clinical practice. These factors collectively secure North America’s leading position in the industry.

Recent Developments

• In September 2024, Illumina, Inc. entered into a strategic partnership with LGC Biosearch Technologies to accelerate the adoption of genomics in the agricultural industry. The collaboration focused on combining LGC's targeted genotyping-by-sequencing library preparation technology with Illumina's high-capacity sequencing platforms. This joint effort aimed to provide researchers and breeders in the Asia Pacific and Latin America regions with a scalable and efficient method for genotyping plants and livestock. By integrating these technologies, the companies sought to deliver cost-effective solutions that improve crop yields and enhance breeding programs, addressing critical challenges in global food security and sustainability.
• In April 2024, Eurofins Genomics AgriGenomics Europe announced a strategic partnership with Gencove to offer an advanced solution for low-pass whole genome sequencing in Europe. This collaboration combined the partner's data analytics and management platform with Eurofins' extensive sequencing infrastructure to deliver a cost-effective and high-throughput alternative to traditional genotyping arrays. The joint offering was designed to support plant and animal breeders by providing comprehensive genomic information that facilitates more accurate selection and trait analysis. This initiative aimed to usher in a new era of genotyping by making large-scale genomic data more accessible and actionable for the agricultural sector.
• In March 2024, Revvity, Inc. introduced a flexible, end-to-end workflow solution specifically designed for newborn sequencing research. This new offering integrated various instruments, reagents, and databases to enable laboratories to identify variants in more than 350 genes associated with rare diseases. The workflow covered essential steps from dried blood spot collection and nucleic acid extraction to library preparation and analysis. By providing a streamlined "sample-to-answer" process, the company aimed to accelerate the democratization of genomic sequencing and support the identification of genetic risks in newborns, which could eventually aid in the diagnosis of childhood-onset conditions.
• In January 2024, Thermo Fisher Scientific launched the Axiom PangenomiX Array to facilitate population-scale disease studies and pharmacogenomic research. This new solution was designed to optimize genetic coverage by combining four distinct assays into a single test, including single nucleotide polymorphism genotyping, whole genome copy number variant detection, and HLA typing. The array aimed to address the growing need for more diverse genomic data sets in healthcare and drug development. By offering a high-throughput and comprehensive view of human genomic variation, the product enabled researchers to better predict disease risks and improve treatment decision-making across varied populations.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN N.V.
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• General Electric Compnay
• Bio-Rad Laboratories Inc.
• Standard BioTools Inc.

By Product	By Technology	By Application	By End Use	By Region
Instruments Reagents & Kits Software and Services	PCR Capillary Electrophoresis Microarrays Sequencing Mass Spectrometry Others	Pharmacogenomics Diagnostics and Personalized Medicine Agricultural Biotechnology Animal Genetics Others	Pharmaceutical and Biopharmaceutical Companies Diagnostics and Research Laboratories Academic Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Genotyping Market, By Product:

• Instruments
• Reagents & Kits
• Software and Services

• Genotyping Market, By Technology:

• PCR
• Capillary Electrophoresis
• Microarrays
• Sequencing
• Mass Spectrometry
• Others

• Genotyping Market, By Application:

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Others

• Genotyping Market, By End Use:

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostics and Research Laboratories
• Academic Institutes
• Others

• Genotyping Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE